Open Access

Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda

  • Sheila Nankoberanyi1, 3,
  • George W Mbogo1, 3,
  • Norbert P LeClair2,
  • Melissa D Conrad2,
  • Patrick Tumwebaze1, 3,
  • Stephen Tukwasibwe1, 3,
  • Moses R Kamya1, 3,
  • Jordan Tappero4,
  • Samuel L Nsobya1, 3 and
  • Philip J Rosenthal2Email author
Malaria Journal201413:95

https://doi.org/10.1186/1475-2875-13-95

Received: 18 November 2013

Accepted: 21 February 2014

Published: 14 March 2014

Abstract

Background

Malaria remains a major public health problem, and its control has been hampered by drug resistance. For a number of drugs, Plasmodium falciparum single nucleotide polymorphisms (SNPs) are associated with altered drug sensitivity and can be used as markers of drug resistance. Several techniques have been studied to assess resistance markers. The most widely used methodology is restriction fragment length polymorphism (RFLP) analysis. The ligase detection reaction fluorescent microsphere (LDR-FM) assay was recently shown to provide high throughput assessment of P. falciparum SNPs associated with drug resistance. The aim of this study was to validate the reliability and accuracy of the LDR-FM assay in a field setting.

Methods

For 223 samples from a clinical trial in Tororo, Uganda in which P. falciparum was identified by blood smear, DNA was extracted from dried blood spots, genes of interest were amplified by PCR, amplicons were analysed by both RFLP and LDR-FM assays, and results were compared.

Results

SNP prevalence (wild type/mixed/mutant) with RFLP analysis was 8/5/87% for pfcrt K76T, 34/37/29% for pfmdr1 N86Y, 64/17/19% for pfmdr1 Y184F, and 42/21/37% for pfmdr1 D1246Y. These prevalences with the LDR-FM assay were 7/5/88%, 31/24/45%, 62/20/18%, and 48/19/33% for the four SNPs, respectively. Combining mixed and mutant outcomes for analysis, agreement between the assays was 97% (K = 0.77) for pfcrt K76T, 79% (K = 0.55) for pfmdr1 N86Y, 83% (K = 0.65) for pfmdr1 Y184F, and 91% (K = 0.82) for pfmdr1 D1246Y, with most disagreements due to discrepant readings of mixed genotypes.

Conclusion

The LDR-FM assay provides a high throughput, relatively inexpensive and accurate assay for the surveillance of P. falciparum SNPs associated with drug resistance in resource-limited countries.

Keywords

Plasmodium falciparum Malaria Fluorescent microsphere assay Drug resistance Polymorphisms

Background

Malaria, especially that caused by Plasmodium falciparum, remains one of the most important infectious diseases in the world. The treatment and control of malaria has been greatly hampered by parasite resistance to available drugs. With widespread resistance to older drugs, artemisinin-based combination therapy (ACT) is now the standard of care for the treatment of falciparum malaria. In Uganda, artemether-lumefantrine (AL) was introduced as first-line treatment for uncomplicated malaria in 2006 [1].

Mechanisms of resistance to anti-malarial drugs are incompletely understood. For chloroquine and amodiaquine, the K76T mutation in the pfcrt gene, which encodes a putative drug transporter, is the principal mediator of resistance [2]. Polymorphisms in another gene, pfmdr1, which encodes a protein homologous to transporters that mediate drug resistance in other organisms, modulate levels of sensitivity to multiple drugs [3]. In Africa, the pfmdr1 N86Y, Y184F and D1246Y polymorphisms are common, and the 86Y and 1246Y mutations are associated with decreased sensitivity to chloroquine and amodiaquine [46]. Interestingly, wild type sequences at these same alleles lead to decreased sensitivity to artemisinins and the ACT partner drugs lumefantrine and mefloquine [5, 7, 8]. Given the limited arsenal of effective ACT and early signs of artemisinin resistance in Southeast Asia [9, 10], there is a need for efficient surveillance of Ugandan parasites for genetic polymorphisms that may mediate resistance to the most important anti-malarial drugs.

Several techniques have been developed to detect single nucleotide polymorphisms (SNPs) associated with P. falciparum drug resistance. The most widely used is restriction fragment length polymorphism (RFLP) analysis [11], which is reliable, but fairly expensive and labour intensive. Other relatively low throughput methodologies include direct DNA sequencing, mutation-specific PCR [12], dot-blot probe hybridization [13], molecular beacons [14], and single-nucleotide primer extension [15]. Other techniques that have provided improved throughput include polymorphism-specific microarrays [16], melting curve analysis [17, 18] and quantitative PCR [1921]. Each of these methodologies has challenges, especially in resource-limited settings, including cost and availability of required instruments.

The ligase detection reaction fluorescent microsphere (LDR-FM) assay allows multiplex assessment of multiple P. falciparum SNPs [22]. It was recently shown that this assay is accurate and also less expensive and less labour intensive compared to RFLP analysis [23]. This new study compared the LDR-FM assay with RFLP analysis for the detection of key resistance-mediating P. falciparum SNPs in samples from a Ugandan clinical trial, with assays performed in parallel at a Ugandan laboratory.

Methods

Samples for analysis

Control parasite DNA was obtained from the Malaria Research and Reference Reagent Resource Center. Field samples were from a longitudinal anti-malarial drug efficacy trial in Tororo, Uganda, the details of which have been published [24]. Briefly, 351 children aged four to 12 months were enrolled and randomized to receive either AL or dihydroartemisinin-piperaquine (DP) for each episode of uncomplicated malaria between 2007 and 2012.

All first episodes of falciparum malaria and all recurrent malaria episodes presenting 84 or more days after prior treatment were studied. Parasite densities were estimated by counting the number of asexual parasites per 200 white blood cells and calculating parasites per μL, assuming a white blood cell count of 8,000 cells/μL. The study was approved by the Uganda National Council of Science and Technology and the Institutional Review Boards of Makerere University College of Health Sciences and the University of California, San Francisco, USA.

RFLP analysis

DNA was extracted from filter paper with Chelex resin [25] and alleles were identified by nested PCR (see Additional file 1 for primers) followed by RFLP analysis, as previously described [26, 27]. Briefly, regions of interest were amplified, PCR products were treated with polymorphism-specific restriction endonucleases (Apo I for pfcrt K76T, Afl III for pfmdr1 N86Y, Dra I for pfmdr1 Y184F, and Bgl II for pfmdr1 D1246Y), and the sizes of products were characterized by agarose gel electrophoresis to distinguish wild type, mutant and mixed alleles based on comparison with control reference strain DNA.

LDR-FM analysis

The extracted DNA was amplified by PCR (see Additional file 2 for primers), as previously described [23]. The amplicons were subjected to multiplex ligase detection reactions (see Additional file 3 for primers) in which bead-specific oligonucleotides and biotin were added, ligation products were hybridized to magnetic beads, and polymorphism prevalences were assessed fluorometrically in a multiplex format using a Magpix instrument (Luminex). Genotypes were determined based on comparisons with controls, with a minimum threshold of 400 MFI for each reaction and correction factors for each SNP, as previously described [23].

Statistical analysis

Correlation of results between assays was assessed using kappa statistics.

Results

Analysis of plasmodium falciparum reference strains

The goal of this study was to validate the LDR-FM assay, using samples from a recent clinical trial, with assays performed at a molecular laboratory in Kampala, Uganda. The LDR-FM assay was first evaluated with DNA from laboratory adapted P. falciparum strains 3D7, 7G8, DD2 and V1/S. Three SNPs in pfmdr1 that are common in Uganda and a five-amino acid haplotype in pfcrt that distinguishes chloroquine-sensitive and -resistant parasites with different geographic backgrounds were assessed [28]. Sequence determinations at all studied polymorphisms were straightforward, with background readings for unidentified SNPs five to ten-fold lower than the readings for correct identifications (Table 1).
Table 1

LDR-FM readings for four SNPs in Plasmodium falciparum reference strains

Strain

pfmdr 1

pfcrt

 

86 N

86Y

184Y

184 F

1246D

1246Y

CVMNK

CVIET

SVMNT

3D7

4,325

119

3,316

251

3,720

191

1,330

237

281

7G8

3,680

187

197

4,087

123

1,452

458

741

3,133

DD2

214

1,689

3,810

256

4,773

153

210

2,660

214

V1/S

126

4,018

3,679

284

3,599

193

309

2,647

315

Values shown are uncorrected mean fluorescence readings for three to five assays, each run in triplicate. For pfcrt, the haplotype represents amino acids 72–76. Readings representing the known sequences at each allele are in bold type.

Analysis of clinical samples

A total of 230 smear-positive clinical samples were analysed by both RFLP and LDR-FM assays. The characteristics describing these samples are shown in Table 2. Representative uncorrected fluorescence data for ten samples showed generally good discrimination of wild type, mixed and mutant genotypes (Table 3). Results were available from 223 samples for both assays and these were used for comparisons. Assays were unsuccessful for six RFLP and zero LDR-FM assays for pfcrt, seven RFLP and seven LDR-FM assays at pfmdr1 86, seven RFLP and seven LDR-FM assays at pfmdr1 184, and three RFLP and one LDR-FM assays at pfmdr1 1246. SNP prevalences measured by RFLP analysis and with the LDR-FM assay were similar at all studied alleles (Table 4). Agreement between the assays was good, although results varied between the studied alleles (Figure 1). Most discrepancies were due to a mixed reading with one assay, compared to a pure mutant or wild type reading with the other assay. Combining mixed and mutant outcomes for analysis, agreement between the assays was 97% (K = 0.77) for pfcrt K76T, 79% (K = 0.55) for pfmdr1 N86Y, 83% (K = 0.65) for pfmdr1 Y184F, and 91% (K = 0.82) for pfmdr1 D1246Y.
Table 2

Baseline characteristics of the samples utilized in this study

Characteristic

Treatment arm

 

AL (n = 101)

DP (n = 129)

Mean age, months ± SD

30.4 ± 14

30.4 ± 14

Mean parasite density, geometric mean cells/μl (IQR)

18,534 (8160–74,277)

14,164 (4720–60,800)

Mean time since last episode of malaria, days

174

166

Year of collection

2008-2012

2008-2012

Mean time between collection and assay (range)

3.7 years (1–5)

3.6 years (1–5)

AL artemether-lumefantrine; DP dihydroartemisinin-piperaquine; IQR inter-quartile range; SD standard deviation.

Table 3

Representative LDR-FM results for ten clinical samples

Sample

Parasite density (per μl)

pfmdr1

pfcrt

  

86 N

86Y

184Y

184 F

1246D

1246Y

CVMNK

CVIET

SVMNT

1

12,560

3,386

106

3,600

209

2,018

101

1,235

231

174

2

74,080

1,849

1,885

2,083

2,284

3,286

309

811

1,678

195

3

35,120

812

2,937

177

4,031

4,140

365

232

2,115

195

4

8,960

3,761

188

2,879

3,361

4,536

164

207

2,311

214

5

24,560

4,081

125

4,068

322

3,386

93

162

2,438

163

6

1,440

143

3,777

4,024

292

115

2,065

222

2,430

164

7

25,520

1,502

3,754

3,928

1,788

2,496

1,881

304

2,440

163

8

36,064

2,829

2,846

311

5,227

3,148

937

1,119

1,610

211

9

18,320

2,677

132

3,154

555

4,254

143

1,097

1,262

243

10

14,840

4,121

100

3,686

267

196

1,715

1,385

317

231

Values shown are uncorrected mean fluorescence readings. Readings representing the sequence call at each allele after correction by subtraction of background are in bold type.

Table 4

Genotype results as analysed by RFLP and LDR-FM assays

Genotype

pfcrt K76T

pfmdr1 N86Y

pfmdr1 Y184F

pfmdr1 D1246Y

 

RFLP

LDR-FM

RFLP

LDR-FM

RFLP

LDR-FM

RFLP

LDR-FM

Wild type

17 (8%)

16 (7%)

76 (34%)

69 (31%)

143 (64%)

139 (62%)

94 (42%)

107 (48%)

Mixed

12 (5%)

11 (5%)

83 (37%)

53 (24%)

38 (17%)

45 (20%)

47 (21%)

42 (19%)

Mutant

194 (87%)

196 (88%)

64 (29%)

101 (45%)

42 (19%)

39 (18%)

82 (37%)

74 (33%)

The numbers of samples with each genotype and percentages of total assignments are shown.

Figure 1

Agreement between RFLP and LDR-FM assays. Results are shown for samples with readings from both assays at the indicated alleles.

Discussion

The aim of this study was to validate the LDR-FM assay for the detection of SNPs associated with anti-malarial drug resistance in a Ugandan laboratory. A total of 230 smear-positive clinical samples were analysed for four SNPs associated with anti-malarial drug resistance using RFLP and LDR-FM assays, and results were compared. It is important to note that both systems have potential for errors in misclassification, in particular due to challenges in distinguishing pure and mixed genotypes at each allele of interest. As seen in a prior study, SNP prevalences measured by RFLP and LDR-FM analyses were similar at the studied alleles, with most discrepancies between assays due to different calls for mixed genotypes, and with DNA sequencing showing that for 8 of 9 discrepant readings the LDR-FM result was correct [23].

Several techniques have been assessed to detect SNPs associated with P. falciparum anti-malarial drug resistance, each with potential advantages and disadvantages in a resource-limited setting. Of particular importance is availability of equipment necessary for high throughput methods. The LDR-FM assay requires an expensive device, but this unit can provide a range of assays, including measurements of serum cytokine levels and antibody reactivity, suggesting that it will be of value for many field-based laboratories. Reagent costs for the LDR-FM assay are also significant, but this is the case with all molecular assays, and recent estimates suggested that the assay provides results at about half the reagent costs of RFLP assessments [23]. Further, throughput was estimated to be five to ten-fold better with the LDR-FM assay compared to RFLP analysis, offering large potential savings in personnel costs.

Conclusions

The LDR-FM assay, when performed in a developing-world laboratory, provided accurate assessment of SNPs associated with anti-malarial drug resistance. This method offers relatively high throughput and low cost, hence it will be used for large-scale surveillance of P. falciparum polymorphisms of interest in ongoing studies in Uganda [29]. For other field-based laboratories with access to Magpix instrumentation, this system may offer the most practical means of large-scale surveillance of P. falciparum genetic polymorphisms.

Abbreviations

RFLP: 

Restriction fragment length polymorphism

LDR-FM: 

Ligase detection reaction fluorescent microsphere

SNP: 

Single nucleotide polymorphism

AL: 

Artemether-lumefantrine

DP: 

Dihydroartemisinin-piperaquine

ACT: 

Artemisinin-based combination therapy.

Declarations

Acknowledgments

We thank the children studied in the clinical trial that provided samples for our analyses, their parents or guardians, the study personnel and the molecular biology team in Kampala for their assistance during the study. This study was funded by an International Center of Excellence in Malaria Research grant (AI089674) and a Fogarty International Center training grant (TW007375), both from the National Institutes of Health. The clinical trial that provided samples for this study was funded by the Centers for Disease Control and Prevention and the Doris Duke Charitable Foundation.

Authors’ Affiliations

(1)
Infectious Diseases Research Collaboration
(2)
Department of Medicine, University of California
(3)
Makerere University
(4)
Centers for Disease Control and Prevention, Center for Global Health

References

  1. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsobya S, Staedke SG, Donnelly MJ, Wabwire-Mangen F, Talisuna A, Dorsey G, Kamya MR, Rosenthal PJ: Malaria in Uganda: Challenges to control on the long road to elimination. I. Epidemiology and current control efforts. Acta Trop. 2012, 121: 184-195. 10.1016/j.actatropica.2011.03.004.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Valderramos SG, Fidock DA: Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci. 2006, 27: 594-601. 10.1016/j.tips.2006.09.005.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ: Roles of specific plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg. 2006, 75: 162-165.PubMedGoogle Scholar
  5. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL: Amodiaquine and artemether-lumefantrine select distinct alleles of the plasmodium falciparum mdr1 gene in tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007, 51: 991-997. 10.1128/AAC.00875-06.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ: Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J Infect Dis. 2009, 200: 1650-1657. 10.1086/647988.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection of plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006, 50: 1893-1895. 10.1128/AAC.50.5.1893-1895.2006.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A: In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009, 53: 5069-5073. 10.1128/AAC.00638-09.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008, 359: 2619-2620. 10.1056/NEJMc0805011.View ArticlePubMedGoogle Scholar
  10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Duraisingh MT, Curtis J, Warhurst DC: Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998, 89: 1-8. 10.1006/expr.1998.4274.View ArticlePubMedGoogle Scholar
  12. Dorsey G, Kamya MR, Singh A, Rosenthal PJ: Polymorphisms in the plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis. 2001, 183: 1417-1420. 10.1086/319865.View ArticlePubMedGoogle Scholar
  13. Ranford-Cartwright LC, Johnston KL, Abdel-Muhsin AM, Khan BK, Babiker HA: Critical comparison of molecular genotyping methods for detection of drug-resistant plasmodium falciparum. Trans R Soc Trop Med Hyg. 2002, 96: 568-572. 10.1016/S0035-9203(02)90446-3.View ArticlePubMedGoogle Scholar
  14. Durand R, Eslahpazire J, Jafari S, Delabre JF, Marmorat-Khuong A, di Piazza JP, Le Bras J: Use of molecular beacons to detect an antifolate resistance-associated mutation in plasmodium falciparum. Antimicrob Agents Chemother. 2000, 44: 3461-3464. 10.1128/AAC.44.12.3461-3464.2000.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Nair S, Brockman A, Paiphun L, Nosten F, Anderson TJ: Rapid genotyping of loci involved in antifolate drug resistance in plasmodium falciparum by primer extension. Int J Parasitol. 2002, 32: 852-858. 10.1016/S0020-7519(02)00033-4.View ArticlePubMedGoogle Scholar
  16. Crameri A, Marfurt J, Mugittu K, Maire N, Regos A, Coppee JY, Sismeiro O, Burki R, Huber E, Laubscher D, Puijalon O, Genton B, Felger I, Beck HP: Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol. 2007, 45: 3685-3691. 10.1128/JCM.01178-07.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Decuypere S, Elinck E, Van Overmeir C, Talisuna AO, D’Alessandro U, Dujardin JC: Pathogen genotyping in polyclonal infections: application of a fluorogenic polymerase-chain-reaction assay in malaria. J Infect Dis. 2003, 188: 1245-1249. 10.1086/378521.View ArticlePubMedGoogle Scholar
  18. Daniels R, Ndiaye D, Wall M, McKinney J, Sene PD, Sabeti PC, Volkman SK, Mboup S, Wirth DF: Rapid, field-deployable method for genotyping and discovery of single-nucleotide polymorphisms associated with drug resistance in plasmodium falciparum. Antimicrob Agents Chemother. 2012, 56: 2976-2986. 10.1128/AAC.05737-11.PubMed CentralView ArticlePubMedGoogle Scholar
  19. de Monbrison F, Raynaud D, Latour-Fondanaiche C, Staal A, Favre S, Kaiser K, Peyron F, Picot S: Real-time PCR for chloroquine sensitivity assay and for pfmdr1-pfcrt single nucleotide polymorphisms in plasmodium falciparum. J Microbiol Methods. 2003, 54: 391-401. 10.1016/S0167-7012(03)00086-1.View ArticlePubMedGoogle Scholar
  20. Purfield A, Nelson A, Laoboonchai A, Congpuong K, McDaniel P, Miller RS, Welch K, Wongsrichanalai C, Meshnick SR: A new method for detection of pfmdr1 mutations in plasmodium falciparum DNA using real-time PCR. Malar J. 2004, 3: 9-10.1186/1475-2875-3-9.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Kamau E, Alemayehu S, Feghali KC, Tolbert LS, Ogutu B, Ockenhouse CF: Development of a TaqMan allelic discrimination assay for detection of single nucleotides polymorphisms associated with anti-malarial drug resistance. Malar J. 2012, 11: 23-10.1186/1475-2875-11-23.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Carnevale EP, Kouri D, DaRe JT, McNamara DT, Mueller I, Zimmerman PA: A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with plasmodium falciparum drug resistance. J Clin Microbiol. 2007, 45: 752-761. 10.1128/JCM.01683-06.PubMed CentralView ArticlePubMedGoogle Scholar
  23. LeClair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SL, Rosenthal PJ: Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of plasmodium falciparum. J Clin Microbiol. 2013, 51: 2564-2570. 10.1128/JCM.00904-13.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009, 49: 1629-1637. 10.1086/647946.View ArticlePubMedGoogle Scholar
  25. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995, 52: 565-568.PubMedGoogle Scholar
  26. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001, 344: 257-263. 10.1056/NEJM200101253440403.View ArticlePubMedGoogle Scholar
  27. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: The tyrosine-86 allele of the pfmdr1 gene of plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000, 108: 13-23. 10.1016/S0166-6851(00)00201-2.View ArticlePubMedGoogle Scholar
  28. Mehlotra RK, Mattera G, Bockarie MJ, Maguire JD, Baird JK, Sharma YD, Alifrangis M, Dorsey G, Rosenthal PJ, Fryauff DJ, Kazura JW, Stoneking M, Zimmerman PA: Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite plasmodium falciparum. Antimicrob Agents Chemother. 2008, 52: 2212-2222. 10.1128/AAC.00089-08.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Talisuna A, Adibaku S, Dorsey G, Kamya MR, Rosenthal PJ: Malaria in Uganda: challenges to control on the long road to elimination. II. The path forward. Acta Trop. 2012, 121: 196-201. 10.1016/j.actatropica.2011.06.013.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Nankoberanyi et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement